Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1536.

https://doi.org/10.1182/blood-2023-184678

Published: 2023

Journal Articles

Multicenter Campus ALL Study on Infectious Complications in Ph- Acute Lymphoblastic Leukemia Patients Treated in the Real Life with the Gimema LAL1913 Protocol

Blood (2023) 142 (Supplement 1): 5877.

https://doi.org/10.1182/blood-2023-182976

Published: 2023

Journal Articles

Study of Venetoclax Plasma Concentrations during Co-Administration with Posaconazole in Acute Myeloid Leukemia (AML) Patients

Patrizia Zappasodi, Simona De Gregori, Eleonora Gelli, Elisa Roncoroni, Marianna Rossi, Claudia Patricia Tobar Cabrera, Eugenio Santacroce, Gianluca Martini, Ludovica Calabretta, Riccardo Albertini, Luca Arcaini

Blood (2022) 140 (Supplement 1): 11528–11529.

https://doi.org/10.1182/blood-2022-162544

Published: 2022

Journal Articles

Clinical relevance of clonal hematopoiesis in persons aged ≥80 years

Marianna Rossi, Manja Meggendorfer, Matteo Zampini, Mauro Tettamanti, Emma Riva, Erica Travaglino, Matteo Bersanelli, Sara Mandelli, Alessia Antonella Galbussera, Ettore Mosca, Elena Saba, Chiara Chiereghin, Nicla Manes, Chiara Milanesi, Marta Ubezio, Lucio Morabito, Clelia Peano, Giulia Soldà, Rosanna Asselta, Stefano Duga, Carlo Selmi, Maria De Santis, Karolina Malik, Giulia Maggioni, Marilena Bicchieri, Alessia Campagna, Cristina A. Tentori, Antonio Russo, Efrem Civilini, Paola Allavena, Rocco Piazza, Giovanni Corrao, Claudia Sala, Alberto Termanini, Laura Giordano, Paolo Detoma, Aurelio Malabaila, Luca Sala, Stefano Rosso, Roberto Zanetti, Claudia Saitta, Elena Riva, Gianluigi Condorelli, Francesco Passamonti, Armando Santoro, Francesc Sole, Uwe Platzbecker, Pierre Fenaux, Niccolò Bolli, Gastone Castellani, Wolfgang Kern, George S. Vassiliou, Torsten Haferlach, Ugo Lucca, Matteo G. Della Porta

Blood (2021) 138 (21): 2093–2105.

https://doi.org/10.1182/blood.2021011320

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population: Analysis of the "Health and Anemia" Study

Blood (2018) 132 (Supplement 1): 750.

https://doi.org/10.1182/blood-2018-99-114717

Published: 2018

Journal Articles

Effects of the Switch to Generic Imatinib in a Cohort of 109 Italian CML Patients - the Gims Study

Maria Gemelli, MD, Chiara Elena, MD, Margherita Maffioli, MD, Cristina Bucelli, MD, Marianna Rossi, MD, Mattia Bacciocchi, Elena Maria Elli, MD, Maria Grazia Valsecchi, PhD, Laura Antolini, PhD, Carlo Gambacorti-Passerini, MD

Blood (2018) 132 (Supplement 1): 4266.

https://doi.org/10.1182/blood-2018-99-115208

Published: 2018

Journal Articles

Clinical Implications of TP53 Mutations and p53 Dysfunction in Patients with Myelodysplastic Syndrome (MDS). a Study from the Italian MDS Clinical Network

Blood (2017) 130 (Supplement 1): 2959.

https://doi.org/10.1182/blood.V130.Suppl_1.2959.2959

Published: 2017

Journal Articles

Additional Prognostic Impact of the Percentage of Erythroid Cells in the Bone Marrow of MDS Patients

Judith Neukirchen, MD, Heinz Tuechler, Matteo Giovanni Della Porta, MD, Pierre Fenaux, MD PhD, Ulrich Germing, MD, Agnès Guerci, Kathrin Nachtkamp, MD, Marianna Rossi, MD, Rosa Sapena, Wolfgang R. Sperr, MD, Corinna Strupp, MD, Aspasia Stamatoullas, MD, Peter Valent, MD, John M. Bennett, MD

Blood (2017) 130 (Supplement 1): 4259.

https://doi.org/10.1182/blood.V130.Suppl_1.4259.4259

Published: 2017

Journal Articles

Driver Somatic Mutations and Transplantation Decision Making in Patients with Myelodysplastic Syndrome

Blood (2016) 128 (22): 53.

https://doi.org/10.1182/blood.V128.22.53.53

Published: 2016

Journal Articles

Real Life Analysis of the Rete Ematologica Lombarda on ELN Favorable Acute Myeloid Leukemia: The Molecular Remission Is a Necessary Goal for a Good Outcome in All Different Cytogenetic/Molecular Subgroups

Patrizia Zappasodi, MD, Laura Marbello, MD, Erika Borlenghi, MD, Monica Fumagalli, MD, Massimo Bernardi, MD, Nicola Stefano Fracchiolla, MD, Matteo Da Vià, MD, Marianna Rossi, MD, Emanuele Ravano, MD, Elisa Cerqui, MD, Virginia Valeria Ferretti, PhD, Mario Cazzola, Prof, Carlo Castagnola, MD, Giuseppe Rossi, MD

Blood (2015) 126 (23): 3740.

https://doi.org/10.1182/blood.V126.23.3740.3740

Published: 2015

Journal Articles

Can Allo-HSCT Improve the Poor Clinical Outcome of the “Internal Tandem Duplication” of the FLT3 Gene?

Paolo Bernasconi, MD, Catherine Klersy, MD, Anna Amelia Colombo, MD, Daniela Caldera, MD, Francesco Ripamonti, MD, Patrizia Zappasodi, MD, Barbara Rocca, BSc, Celeste Calvello, BSc, Matteo Giovanni Della Porta, Marianna Rossi, MD, Manuela Santantonio, MD, Irene Dambruoso, Rita Zappatore, PhD, Mirko Farina, Daniela Troletti, BSc, Marina Boni, Carlo Castagnola, MD, Emilio Paolo Alessandrino, MD

Blood (2014) 124 (21): 5938.

https://doi.org/10.1182/blood.V124.21.5938.5938

Published: 2014

Journal Articles

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Blood (2014) 123 (21): 3247–3254.

https://doi.org/10.1182/blood-2014-01-546150

Published: 2014

Includes: Supplemental data

Journal Articles

A Phase II Multi-Center Trial Of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) In Older Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Marco Montillo, MD, Davide Rossi, Marina Motta, MD, Giulia Quaresmini, MD, Marianna Rossi, MD, Marta Coscia, MD, PhD, Antonella Anastasia, MD, Fausto Rossini, MD, Agostino Cortelezzi, MD, Guido Nador, MD, Lydia Scarfò, MD, Roberto Cairoli, MD, Daniela Dal Ceggio, MD, Lorenzo De Paoli, MD, Enrica Morra, MD, Alessandro Rambaldi, MD, Ester Orlandi, MD, Massimo Massaia, MD, Alessandra Tedeschi, MD

Blood (2013) 122 (21): 4177.

https://doi.org/10.1182/blood.V122.21.4177.4177

Published: 2013

Journal Articles

NOTCH1 , SF3B1 , and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG

Andrea Schnaiter, Peter Paschka, Marianna Rossi, Thorsten Zenz, Andreas Bühler, Dirk Winkler, Mario Cazzola, Konstanze Döhner, Jennifer Edelmann, Daniel Mertens, Sabrina Kless, Silja Mack, Raymonde Busch, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer

Blood (2013) 122 (7): 1266–1270.

https://doi.org/10.1182/blood-2013-03-488197

Published: 2013

Includes: Supplemental data

Journal Articles

TP53 , SF3B1 , and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

Blood (2013) 121 (16): 3284–3288.

https://doi.org/10.1182/blood-2012-11-469627

Published: 2013

Includes: Supplemental data

Journal Articles

Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms

Mario Cazzola, Marianna Rossi, Luca Malcovati

Blood (2013) 121 (2): 260–269.

https://doi.org/10.1182/blood-2012-09-399725

Published: 2013

Journal Articles

Incidence and Clinical Significance of SF3B1 Somatic Mutation in Chronic Lymphocytic Leukemia.

Marianna Rossi, Ester M Orlandi, Peter Paschka, Silvia Zibellini, Cristiana Pascutto, Konstanze Doehner, Mario Cazzola

Blood (2012) 120 (21): 2881.

https://doi.org/10.1182/blood.V120.21.2881.2881

Published: 2012

Journal Articles

Human Telomerase Reverse Transcriptase (hTERT): A New Potential Prognostic Marker in AML?

Paolo Bernasconi, Catherine Klersy, MD, Barbara Rocca, BSc, Celeste Calvello, BSc, Antonella Orlando, Marina Boni, Irene Dambruoso, Marianna Rossi, Paola Maria Cavigliano, PhD, Ilaria Giardini, PhD, Patrizia Zappasodi, MD, Rita Zappatore, PhD, Marilena Caresana, PhD, Carlo Castagnola

Blood (2012) 120 (21): 4790.

https://doi.org/10.1182/blood.V120.21.4790.4790

Published: 2012

Journal Articles

SF3B1 , NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial

Peter Dreger, MD, Andrea Schnaiter, MD, Marianna Rossi, Peter Paschka, Andreas Bühler, MD, Thorsten Zenz, MD, Sascha Dietrich, MD, Sebastian Böttcher, MD, Donald Bunjes, Michael Stadler, MD, Lutz Uharek, MD, Christof Scheid, MD, PhD, Ute Hegenbart, MD, Michael Hallek, MD, Michael Kneba, MD, PhD, Norbert Schmitz, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2012) 120 (21): 966.

https://doi.org/10.1182/blood.V120.21.966.966

Published: 2012

Journal Articles

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Blood (2012) 120 (21): 433.

https://doi.org/10.1182/blood.V120.21.433.433

Published: 2012

NARROW

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Multicenter Campus ALL Study on Infectious Complications in Ph- Acute Lymphoblastic Leukemia Patients Treated in the Real Life with the Gimema LAL1913 Protocol

Study of Venetoclax Plasma Concentrations during Co-Administration with Posaconazole in Acute Myeloid Leukemia (AML) Patients

Clinical relevance of clonal hematopoiesis in persons aged ≥80 years

Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population: Analysis of the "Health and Anemia" Study

Effects of the Switch to Generic Imatinib in a Cohort of 109 Italian CML Patients - the Gims Study

Clinical Implications of TP53 Mutations and p53 Dysfunction in Patients with Myelodysplastic Syndrome (MDS). a Study from the Italian MDS Clinical Network

Additional Prognostic Impact of the Percentage of Erythroid Cells in the Bone Marrow of MDS Patients

Driver Somatic Mutations and Transplantation Decision Making in Patients with Myelodysplastic Syndrome

Real Life Analysis of the Rete Ematologica Lombarda on ELN Favorable Acute Myeloid Leukemia: The Molecular Remission Is a Necessary Goal for a Good Outcome in All Different Cytogenetic/Molecular Subgroups

Can Allo-HSCT Improve the Poor Clinical Outcome of the “Internal Tandem Duplication” of the FLT3 Gene?

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

A Phase II Multi-Center Trial Of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) In Older Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients

NOTCH1 , SF3B1 , and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG

TP53 , SF3B1 , and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms

Incidence and Clinical Significance of SF3B1 Somatic Mutation in Chronic Lymphocytic Leukemia.

Human Telomerase Reverse Transcriptase (hTERT): A New Potential Prognostic Marker in AML?

SF3B1 , NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only